PMID: 11918534Mar 29, 2002Paper

Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells

British Journal of Haematology
Francesca Maria RossiValter Gattei

Abstract

CD30 ligand (CD30L), but not its cognate receptor CD30, is frequently expressed on acute myeloid leukaemia (AML) blasts. In the present study, we found that leukaemic blasts presenting surface CD30L displayed a characteristic cytokine-receptor pattern that makes them ideal targets for those cytokines usually produced by Th2-type cell subsets. In particular, even though a broad distribution of Th2 cytokine receptors by AML blasts was shown, we demonstrated the almost exclusive expression of interleukin 4 (IL-4) receptor (R), in the absence of its cognate cytokine, by CD30L+ AML. Furthermore, a number of Th2-associated markers, including CD30, IL-4 and GATA-3, were expressed by residual T cells derived from CD30L+ AML but not from CD30L- AML, in which the presence of the Th1-associated marker LAG-3 was documented in some cases. The production of IL-4 in the absence of interferon gamma (IFN-gamma) was also detected in CD3+/CD30+ T cells from CD30L+ AML. These results, along with the shift toward IL-4-producing specific T-cell clones observed in CD30L+ AML samples by enzyme-linked Immunospot (ELISpot) assay, were consistent with the hypothesis of a Th2 polarization taking place in T cells from CD30L+ AML. The notion that IL-4 was a...Continue Reading

References

Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·A PintoY S Cho-Chung
Jun 1, 1992·Leukemia Research·E MontserratC Rozman
Feb 1, 1995·Immunology Today·G Del PreteS Romagnani
Jun 1, 1994·Current Opinion in Immunology·R J Armitage
May 20, 1994·Cell·E Ruoslahti, J C Reed
May 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·F AnnunziatoS Romagnani
Feb 1, 1996·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·H T HassanM Freund
Jan 1, 1996·Advances in Immunology·R A Henderson, O J Finn
Mar 1, 1996·Immunology Today·T R Mosmann, S Sad
Jun 1, 1997·Immunology Today·S Romagnani
Oct 7, 1997·The Journal of Experimental Medicine·M A Degli-EspostiC A Smith
Nov 20, 1998·BioTechniques·J E VaqueranoS P Leong
Jul 6, 2000·Cancer Immunology, Immunotherapy : CII·X L ZhangM Sakurai
Oct 25, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·H MutaE R Podack
Jan 1, 1991·Leukemia & Lymphoma·S D Griffiths, J C Cawley

❮ Previous
Next ❯

Citations

Nov 16, 2006·Cancer Biotherapy & Radiopharmaceuticals·Anna Maria BerghellaDomenico Adorno
Apr 3, 2003·British Journal of Haematology·Ruth PettengellUNKNOWN Haemato-Oncology Task Force of the British Committee for Standards in Haematology
Jan 22, 2004·Experimental Biology and Medicine·Satei Moqattash, John D Lutton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.